Cancer Drug Targets in Cytokines & Growth Factors

Cytokines & Growth Factors are a net-work of tissue-specific regulators, controlling cell production, location, differentiation and movement. An overproduction of growth factors can lead to an accumulation of inappropriate cellular deposits within a tissue and result in cancer. New therapeutic approaches to cancer involve the use of cytokine antagonists or inhibitors to suppress the proliferation and metastasis of the tumor cells and make the cancer cells more susceptible to killing by cytotoxic agents.
Here we list the main cancer drug targets included in cytokines and growth factors. And you also have access to quality reagents through the quick guide below to facilitate your research.

Cytokine drug targets for:

Vital Cancer Drug Targets in Cytokines & Growth Factors


Rantes / CCL5 is associated with cancer progression and metastasis. Rantes / CCL5 interactions with CCR5 may favor tumor development in multiple ways: acting as growth factors, stimulating angiogenesis, modulating the extracellular matrix, inducing the recruitment of additional stromal and inflammatory cells, and……


IL-6 is one of the most ubiquitously deregulated cytokines in cancer, with over-expression of IL-6 observed in virtually every tumor that has been studied. Several investigators have reported an aberrant IL-6 pathway activation in a variety of human cancer cell lines and solid tumors, including epithelial tumors of ovary, breast and……


The binding of VEGF to VEGFR2 is regarded as being critical for the regulation of tumor angiogenesis and the inhibition of this interaction is the main target of anti-VEGF therapeutics. Therapeutics targeting VEGF have improved the therapy of several types of human cancer during recent years.


The proven survival benefit of anti-HER2 driven therapies demonstrated in clinical trials indicates that HER2 is, to date, one of the most promising molecules for targeted therapy. The recombinant humanized monoclonal antibody trastuzumab represents one of the most successful, rationally designed anti-HER2 targeted therapies approved for……


EGFR and its family members are the major contributors of a complex signaling cascade that modulates growth, signaling, differentiation, adhesion, migration and survival of cancer cells. Due to their multi-dimensional role in the progression of cancer, EGFR and its family members have emerged as attractive candidates for anti-cancer therapy.


c-Met/HGFR is involved in many mechanisms of cancer proliferation and metastasis. c-Met/HGFR overexpression and genetic alterations play a role in the pathogenesis of several tumors, including lung cancer. The recent development of c-Met/HGFR-targeted agents offers the potential for improving patient outcomes in cancer

Cancer Drug Targets in Cytokines & Growth Factors Reference

• Burgess A W. Growth factors and cytokines[J]. Reviews in Cell Biology and Molecular Medicine, 2015.
• Aldinucci D, et al. The inflammatory chemokine Rantes and cancer progression[J]. Mediators of inflammation, 2014, 2014.
• Guo Y, et al. Interleukin-6 signaling pathway in targeted therapy for cancer[J]. Cancer treatment reviews, 2012, 38(7): 904-910.
• Waldner M J, et al. Targeting the VEGF signaling pathway in cancer therapy[J]. Expert opinion on therapeutic targets, 2012, 16(1): 5-13.
• Tagliabue E, et al. HER2 as a target for breast cancer therapy[J]. Expert opinion on biological therapy, 2010, 10(5): 711-724.
• Seshacharyulu P, et al. Targeting the EGFR signaling pathway in cancer therapy[J]. Expert opinion on therapeutic targets, 2012, 16(1): 15-31.
• Sattler M, et al. The role of the c-Met pathway in lung cancer and the potential for targeted therapy[J]. Therapeutic advances in medical oncology, 2011, 3(4): 171-184.